598 related articles for article (PubMed ID: 30296182)
1. Semaglutide once-weekly: improved efficacy with a new safety warning.
Coon SA; Crannage EF; Kerwin LC; Guyton JE
Expert Rev Clin Pharmacol; 2018 Nov; 11(11):1061-1072. PubMed ID: 30296182
[TBL] [Abstract][Full Text] [Related]
2. Comparative efficacy, safety, and cardiovascular outcomes with once-weekly subcutaneous semaglutide in the treatment of type 2 diabetes: Insights from the SUSTAIN 1-7 trials.
Aroda VR; Ahmann A; Cariou B; Chow F; Davies MJ; Jódar E; Mehta R; Woo V; Lingvay I
Diabetes Metab; 2019 Oct; 45(5):409-418. PubMed ID: 30615985
[TBL] [Abstract][Full Text] [Related]
3. Sgemaglutide in type 2 diabetes - is it the best glucagon-like peptide 1 receptor agonist (GLP-1R agonist)?
Doggrell SA
Expert Opin Drug Metab Toxicol; 2018 Mar; 14(3):371-377. PubMed ID: 29439603
[TBL] [Abstract][Full Text] [Related]
4. Safety and tolerability of once-weekly GLP-1 receptor agonists in type 2 diabetes.
Trujillo J
J Clin Pharm Ther; 2020 Sep; 45 Suppl 1(Suppl 1):43-60. PubMed ID: 32910487
[TBL] [Abstract][Full Text] [Related]
5. Safety of injectable semaglutide for type 2 diabetes.
Peter R; Bain SC
Expert Opin Drug Saf; 2020 Jul; 19(7):785-798. PubMed ID: 32428416
[TBL] [Abstract][Full Text] [Related]
6. Efficacy and safety of once-weekly semaglutide versus once-daily sitagliptin as an add-on to metformin, thiazolidinediones, or both, in patients with type 2 diabetes (SUSTAIN 2): a 56-week, double-blind, phase 3a, randomised trial.
Ahrén B; Masmiquel L; Kumar H; Sargin M; Karsbøl JD; Jacobsen SH; Chow F
Lancet Diabetes Endocrinol; 2017 May; 5(5):341-354. PubMed ID: 28385659
[TBL] [Abstract][Full Text] [Related]
7. The cost-effectiveness of once-weekly semaglutide compared with other GLP-1 receptor agonists in type 2 Diabetes: a systematic literature review.
Ruan Z; Yang L; Shi H; Yue X; Wang Y; Liang M; Hu H
Expert Rev Pharmacoecon Outcomes Res; 2021 Apr; 21(2):221-233. PubMed ID: 33317348
[No Abstract] [Full Text] [Related]
8. Semaglutide once weekly as add-on to SGLT-2 inhibitor therapy in type 2 diabetes (SUSTAIN 9): a randomised, placebo-controlled trial.
Zinman B; Bhosekar V; Busch R; Holst I; Ludvik B; Thielke D; Thrasher J; Woo V; Philis-Tsimikas A
Lancet Diabetes Endocrinol; 2019 May; 7(5):356-367. PubMed ID: 30833170
[TBL] [Abstract][Full Text] [Related]
9. Semaglutide injection for the treatment of adults with type 2 diabetes.
Chudleigh RA; Bain SC
Expert Rev Clin Pharmacol; 2020 Jul; 13(7):675-684. PubMed ID: 32476529
[TBL] [Abstract][Full Text] [Related]
10. Efficacy and safety of once-weekly semaglutide versus once-daily insulin glargine as add-on to metformin (with or without sulfonylureas) in insulin-naive patients with type 2 diabetes (SUSTAIN 4): a randomised, open-label, parallel-group, multicentre, multinational, phase 3a trial.
Aroda VR; Bain SC; Cariou B; Piletič M; Rose L; Axelsen M; Rowe E; DeVries JH
Lancet Diabetes Endocrinol; 2017 May; 5(5):355-366. PubMed ID: 28344112
[TBL] [Abstract][Full Text] [Related]
11. Glucagon-Like Peptide-1 Receptor Agonists and Cardiovascular Risk Reduction in Type 2 Diabetes Mellitus: Is It a Class Effect?
Li Y; Rosenblit PD
Curr Cardiol Rep; 2018 Sep; 20(11):113. PubMed ID: 30259238
[TBL] [Abstract][Full Text] [Related]
12. Safety of Semaglutide.
Smits MM; Van Raalte DH
Front Endocrinol (Lausanne); 2021; 12():645563. PubMed ID: 34305810
[TBL] [Abstract][Full Text] [Related]
13. Improved treatment satisfaction in patients with type 2 diabetes treated with once-weekly semaglutide in the SUSTAIN trials.
Jendle J; Birkenfeld AL; Polonsky WH; Silver R; Uusinarkaus K; Hansen T; Håkan-Bloch J; Tadayon S; Davies MJ
Diabetes Obes Metab; 2019 Oct; 21(10):2315-2326. PubMed ID: 31215727
[TBL] [Abstract][Full Text] [Related]
14. Comparing once-weekly semaglutide to incretin-based therapies in patients with type 2 diabetes: a systematic review and meta-analysis.
Mishriky BM; Cummings DM; Powell JR; Sewell KA; Tanenberg RJ
Diabetes Metab; 2019 Apr; 45(2):102-109. PubMed ID: 30243806
[TBL] [Abstract][Full Text] [Related]
15. Efficacy and safety of once-weekly semaglutide for the treatment of type 2 diabetes.
Tan X; Cao X; Zhou M; Zou P; Hu J
Expert Opin Investig Drugs; 2017 Sep; 26(9):1083-1089. PubMed ID: 28741970
[TBL] [Abstract][Full Text] [Related]
16. Clinical Perspectives on the Use of Subcutaneous and Oral Formulations of Semaglutide.
Gallwitz B; Giorgino F
Front Endocrinol (Lausanne); 2021; 12():645507. PubMed ID: 34267725
[TBL] [Abstract][Full Text] [Related]
17. Efficacy and safety of once-weekly semaglutide for the treatment of type 2 diabetes: Protocol for a systematic review and meta-analysis.
Shi FH; Li H; Cui M; Zhang ZL; Gu ZC; Liu XY
Medicine (Baltimore); 2018 Apr; 97(16):e0420. PubMed ID: 29668601
[TBL] [Abstract][Full Text] [Related]
18. Semaglutide: The Newest Once-Weekly GLP-1 RA for Type 2 Diabetes.
Tuchscherer RM; Thompson AM; Trujillo JM
Ann Pharmacother; 2018 Dec; 52(12):1224-1232. PubMed ID: 29932006
[TBL] [Abstract][Full Text] [Related]
19. Cardiovascular safety outcomes of once-weekly GLP-1 receptor agonists in people with type 2 diabetes.
Goldman JD
J Clin Pharm Ther; 2020 Sep; 45 Suppl 1(Suppl 1):61-72. PubMed ID: 32910492
[TBL] [Abstract][Full Text] [Related]
20. Cardiovascular risk reduction with once-weekly semaglutide in subjects with type 2 diabetes: a post hoc analysis of gender, age, and baseline CV risk profile in the SUSTAIN 6 trial.
Leiter LA; Bain SC; Hramiak I; Jódar E; Madsbad S; Gondolf T; Hansen T; Holst I; Lingvay I
Cardiovasc Diabetol; 2019 Jun; 18(1):73. PubMed ID: 31167654
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
